Could a diabetes pill protect eyesight in advanced dry AMD?
NCT ID NCT07174687
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can slow the progression of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 70 adults aged 50 and older with this condition will take the drug for 12 months. Researchers will measure changes in retinal damage and vision to see if the treatment is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact